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ARTICLE
Hypoxia inducible factor HIF-1 promotes myeloid-
derived suppressor cells accumulation through
ENTPD2/CD39L1 in hepatocellular carcinoma
David Kung-Chun Chiu1, Aki Pui-Wah Tse1, Iris Ming-Jing Xu1, Jane Di Cui1, Robin Kit-Ho Lai1, Lynna Lan Li1,
Hui-Yu Koh1, Felice Ho-Ching Tsang1, Larry Lai Wei1, Chun-Ming Wong 1,2,
Irene Oi-Lin Ng1,2 & Carmen Chak-Lui Wong1,2
Myeloid-derived suppressor cells (MDSCs) possess immunosuppressive activities, which
allow cancers to escape immune surveillance and become non-responsive to immune
checkpoints blockade. Here we report hypoxia as a cause of MDSC accumulation. Using
hepatocellular carcinoma (HCC) as a cancer model, we show that hypoxia, through
stabilization of hypoxia-inducible factor-1 (HIF-1), induces ectoenzyme, ectonucleoside tri-
phosphate diphosphohydrolase 2 (ENTPD2/CD39L1), in cancer cells, causing its over-
expression in HCC clinical specimens. Overexpression of ENTPD2 is found as a poor
prognostic indicator for HCC. Mechanistically, we demonstrate that ENTPD2 converts
extracellular ATP to 5′-AMP, which prevents the differentiation of MDSCs and therefore
promotes the maintenance of MDSCs. We further ﬁnd that ENTPD2 inhibition is able to
mitigate cancer growth and enhance the efﬁciency and efﬁcacy of immune checkpoint
inhibitors. Our data suggest that ENTPD2 may be a good prognostic marker and therapeutic
target for cancer patients, especially those receiving immune therapy.
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Avoiding immune destruction represents a new hallmark ofcancer. This process is closely associated with thepresence of immune suppressive cells such as myeloid-
derived suppressor cells (MDSCs) and regulatory T (Treg) cells
within the tumor stroma. Hepatocellular carcinoma (HCC),
primary liver cancer, is usually preceded by liver damage
and extensive inﬂammation, and therefore is accompanied by
inﬁltration of immune cells. How multiple immune populations
are maintained in HCC remains largely elusive. Increase of
MDSCs was found in the blood and tumors of HCC patients and
in mice that bear HCC1, 2. MDSCs in HCC were able to inhibit
T and natural killer (NK) cells, and activate Treg cells3, 4. MDSCs
are bone marrow-derived myeloid progenitors. Human MDSCs
are classiﬁed as CD11b+CD33+HLA-DR−, which may co-express
with other markers such as CD15, CD14, CD115, and/or CD1245.
Mouse MDSCs are classiﬁed as CD11b+Gr1+ and could be further
sub-divided into the monocytic (M)-CD11b+Ly6C+Ly6G−
population and the polymorphonuclear (PMN)-CD11b+Ly6G
+Ly6Clo population5. MDSCs represent 30% of cells in the
bone marrow and 2–4% cells in the spleen in normal mice.
MDSCs normally differentiate into granulocytes, macrophages, or
dendritic cells5, 6. However, under pathological conditions such as
cancer, MDSCs become activated, maintain undifferentiation,
and rapidly expand5, 6. In addition to T and NK cells, MDSCs
also suppress dendritic cells. The broad immunosuppressive
effects of MDSCs allow cancer cells to bypass immune surveil-
lance5, 6. More importantly, MDSCs reduce T-cell inﬁltration into
tumor and hence greatly reduce the clinical beneﬁts of immune
checkpoint therapies7. MDSCs also produce high levels of matrix
metalloproteinase 9 (MMP9), which releases angiogenic factor,
vascular endothelial growth factor, from the extracellular matrix,
to promote growth of blood vessels8. A recent study showed that
MDSCs maintain stemness properties of ovarian cancer cells9.
Hypoxia, oxygen (O2) deprivation, is an important environ-
mental factor in HCC. The median O2 partial pressure in human
HCC is 6 mmHg as compared with 30 mmHg in normal liver10.
Regions of HCC frequently receive insufﬁcient O2 supply
as growth of HCC cells often exceeds growth of functional
blood vessels. Common palliative HCC therapies, hepatic artery
ligation (HAL), and transcatheter arterial (chemo) embolization
(TAE/TACE), which initially intend to restrict HCC growth
through blood (nutrient) supply obstruction, undesirably induce
hypoxia. The major molecular mechanism elicit by hypoxia is
through the stabilization of hypoxia-inducible factors (HIFs).
HIFs are heterodimers consisting of an O2-sensitive HIF-1/2α
subunit and a constitutively expressed HIF-1β subunit11. With O2
as the co-substrate, HIF-1/2α subunit is hydroxylated by prolyl
hydroxylases (PHDs)12, allowing the recognition of von
Hippel–Lindau protein (VHL) for ubiquitin-mediated proteoso-
mal degradation of HIF-1/2α13. Decline of O2 stabilizes HIF-1/2α,
which binds to HIF-1β, to initiate transcription of their target
genes14. HIF-1/2α is highly expressed in HCC and is closely
associated with poor clinical outcome in HCC patients. Inhibition
of HIF-1α by oligonucleotides markedly enhanced the efﬁciency
and efﬁcacy of TACE in preclinical animal study15. HIFs, through
inducing various chemokines, tightly orchestrate the immune
context of tumor. HIFs promote Treg inﬁltration through che-
mokine (C–C motif) ligand 28 (CCL28) in ovarian cancer
model16. We demonstrated in HCC model that hypoxic cancer
cells recruit CX3CR1-expressing MDSCs to the tumor through
chemokine (C–C motif) ligand 26 (CCL26)17. We further showed
that obstructing the HCC–MDSC cell communication through
targeting CCL26/CX3CR1 efﬁciently retarded HCC progression17.
Apart from chemokine induction, hypoxia stimulates transport
of ATP into the extracellular space, which has signiﬁcant impact
on the tumor microenvironment. Extracellular ATP is hydrolyzed
to 5′-AMP by ectonucleoside triphosphate diphosphohydrolase
(ENTPD1, CD39), whereas extracellular 5′-AMP is further
hydrolyzed to adenosine by 5′-nucleotidase (NT5E, CD73).
These extracellular metabolites are known to tightly regulate
neurotransmission and immune responses through interacting
with the purigenic (G-coupled) receptors P2 and P1. ATP acts on
the P2 receptor, whereas 5′-AMP and adenosine act on the P1
receptor of immune cells18, 19. Stimulation of P2 or P1 in immune
cells results in very different biological responses, in general,
extracellular ATP activates, whereas adenosine suppresses the
immune system19. Extracellular ATP induces the differentiation
of T cells and promotes the chemotaxis of macrophages and
neutrophils20. Extracellular adenosine hampers the cytotoxicity of
T and NK cells, and activates immune suppressive cells including
MDSCs and Treg cells20. Although the roles of extracellular
5′-AMP are less documented, 5′-AMP is believed to share similar
functions as adenosine due to the same receptors they stimulate20.
Expression of ENTPD1 and NT5E have been shown to be HIF-1α
dependent in epithelial cells19. In cancers, NTPD1 and NT5E,
through creating an adenosine-rich tumor microenvironment,
enable immune cells to escape immune surveillance and promote
tumor survival19. ENTPD inhibitor, through suppressing
ATP conversion to 5′-AMP, restores the recruitment of T and
dendritic cells, and enhances the efﬁciency of chemotherapeutic
agents in ﬁbrosarcoma mouse model21.
Including ENTPD1, there are eight members in the ENTPD
family and four of which have extracellular facing catalytic
domain (ENTPD 1, 2, 3, and 8), but only the roles of ENTPD1 in
cancer has been brieﬂy reported22. Strikingly, we ﬁnd that
ENTPD2, but not the other ENTPD family members and
NT5E, is dramatically overexpressed in HCC. We further show
that hypoxia upregulates ENTPD2 through HIF-1α in HCC
and subsequently leading to the accumulation of extracellular
5′-AMP, which maintains MDSCs undifferentiated. Blocking
ENTPD2 in cancer cells remarkably restrained HCC growth
in vivo. More excitingly, depletion of MDSCs through ENTPD2
inhibitor signiﬁcantly improves the efﬁciency and efﬁcacy of
immune checkpoint inhibitors in vivo. Our study brings three
important messages. First, we disclose a novel mechanism by
which hypoxia/HIF-1α shapes the tumor microenvironment.
Second, we highlight how ENTPD2 is harnessed by cancer cells
to escape immune-mediated destruction. Third, we reveal a
novel therapeutic approach that shows great synergism with
immunotherapies in HCC, a second most deadly cancer which to
date has no promising curative treatments.
Results
ENTPD2 is predominantly expressed under hypoxia in human
HCC. We and others have previously shown that MDSCs
represent an important tumor-residing immune population.
Interestingly, we used HCC as a cancer model to show that
MDSCs favorably inﬁltrate into hypoxic regions of tumors17. We
have further demonstrated that MDSCs are attracted to tumors
through CCL26, whose expression is tightly orchestrated by
HIFs17. This interesting ﬁnding has provided a partial mechan-
istic explanation for the intimate relationship of hypoxia
and MDSC. As MDSCs are prone to differentiation, how intra-
tumoral hypoxia maintains MDSC in undifferentiated status
upon their arrival demands greater understanding. To compre-
hensively parse the roles of hypoxia in MDSC accumulation in
tumors, we investigated the ENTPD family and NT5E, which
have been currently demonstrated as the important contributors
in the immunosuppressive tumor microenvironment23.
From real-time quantitative PCR analysis of three HCC cell
lines, MHCC97L, PLC/PRF/5, and Hep3B, exposed to 20% O2
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(normoxia) and 1% O2 (hypoxia), it was observed that several
members in ENTPD family or NT5E were induced by hypoxia
with ENTPD2 achieving the greatest upregulation consistently in
three HCC cell lines (Fig. 1a and Supplementary Fig. 1a). We also
retrieved data from the TCGA (The Cancer Genome Atlas) in
49 pairs of human HCC tissues and their corresponding
non-tumorous (NT) liver tissues. Clinically, ENTPD2 was also
predominantly overexpressed in HCC patients (Fig. 1b), implying
that ENTPD2 might have a unique role in promoting tumor-
igenesis. Overexpression of ENTPD2 messenger RNA was further
validated in an expanded cohort of 62 HCC patients. TCGA data
showed that ENTPD2 was consistently upregulated in an inde-
pendent cohort of HCC patients (Fig. 1d). More excitingly,
ENTPD2 upregulation was associated with several aggressive
HCC clinico-pathological features including presences of direct
liver invasion, tumor microsatellite formation and venous inva-
sion, as well as the absence of tumor encapsulation (Fig. 1e). High
ENTPD2 expression was also signiﬁcantly correlated with poor
disease-free and overall survival in HCC patients (Fig. 1f).
Immunohistochemistry staining in human HCC cases conﬁrmed
that ENTPD2 was also overexpressed in protein level in human
HCCs relative to their NT counterparts (Fig. 1g) and its staining
followed a typical oxygen diffusion pattern (Supplementary
Fig. 1b) as we reported previously24, suggesting that ENTPD2 is
tightly regulated by hypoxia.
ENTPD2 is a direct transcriptional target of HIF-1α. To
provide additional evidence that ENTPD2 was regulated by
hypoxia, we stained consecutive sections of 10 cases of human
HCCs with ENTPD2 and 2 hypoxia markers including glucose
transporter 1 (GLUT1) and carbonic anhydrase IX (CA9), and
observed a signiﬁcant overlapping staining pattern (Fig. 2a).
ENTPD1 has been demonstrated to be regulated by HIF-1α25. To
conﬁrm whether ENTPD2 is regulated by HIFs, we examined
ENTPD2 mRNA expression in HIFs knockdown and knockout
(KO) HCC cells. We found that the hypoxia-induced ENTPD2
expression could be abrogated upon knockdown or KO of
HIF-1α, but not HIF-2α in MHCC97L cells (Fig. 2b, c and
Supplementary Fig. 2). To conﬁrm whether ENTPD2 is a direct
transcriptional target of HIF-1α, three putative hypoxia-
responsive elements (HREs) containing HIF-1α-binding
consensus sequence 5′-A/GCGTG-3′ in the promoter region
of ENTPD2 were located. Chromatin immunoprecipitation
(ChIP) assay demonstrated the enrichment of hypoxia-inducible
binding of HIF-1α and HIF-1β to these putative HREs in
ENTPD2 (Fig. 2d, e).
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Fig. 1 ENTPD2 expression in HCC. a Real-time quantitative PCR analysis revealed the expression of ENTPD family members and NT5E in three HCC cell
lines, MHCC97L, PLC/PRF/5, and Hep3B, exposed to 20 and 1% O2. Gene expression level was normalized to 20% O2 (n= 3). b TCGA database revealed
the expression of ENTPD family members and NT5E in 49 cases of HCC tissues and their corresponding non-tumorous liver (NT) tissues. Gene expression
level was normalized to NT. cWaterfall plot showed that ENTPD2 was overexpressed in 58% (36/62) of HCC patients. d Left: ENTPD2 mRNA expression
in HCC tissues and their corresponding NT tissues from 62 patients= (Queen Mary Hospital (QMH), the University of Hong Kong (HKU)) was determined
by qRT-PCR. Right: ENTPD2 mRNA expression in HCC and NT tissues in 49 HCC patients from the TCGC database. For qRT-PCR, values were normalized
with house-keeping gene, HPRT. (Wilcoxon signed-rank test, **P< 0.01, ***P< 0.001) e High expression of ENTPD2 was associated with aggressive
clinico-pathological features (n= 62, Student’s t-test). f Data from TCGA showed that high expression (z-score> 1) of ENTPD2 was signiﬁcantly
associated with poorer overall and disease free survival in 368 and 347 HCC patients, respectively (log-rank test, P< 0.01). g Representative IHC staining
images of ENTPD2 in human HCC and NT tissues (10 cases). High ENTPD2 staining was only observed in HCC tissues but not in NT tissues
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ENTPD2 promotes HCC tumor growth and MDSC accumu-
lation. To evaluate the impact of ENTPD2 on HCC tumorigen-
esis, we established ENTPD2 knockdown clones by short hairpin
(sh) RNA approach in two HCC cell lines, MHCC97L (human)
and Hepa1-6 (mouse), without altering the expression of other
ENTPD family members (Supplementary Fig. 3). ENTPD2 had
no direct effects on HCC cell proliferation in vitro (Fig. 3a and
Supplementary Fig. 4). To evaluate the effects of ENTPD2 in
HCC growth in vivo, we orthotopically inoculated the MHCC97L
subclones into BALB/c nude mice and found that knockdown
of ENTPD2 drastically reduced tumor growth (Fig. 3b, c). As
BALB/c nude mice lack T cells and therefore this model might
not be able to fully reﬂect the immunosuppressive roles of
MDSCs, we also performed orthotopic implantation with
ENTPD2 knockdown Hepa1-6 cells in immune-competent
C57BL/6. Notably, ENTPD2 was also upregulated under
hypoxia in mouse HCC cell lines (Supplementary Fig. 5). As
Hepa1-6 was derived from C57BL/6 mice, we found no immune
rejection in this syngeneic model. Concordantly, knockdown of
ENTPD2 in mouse HCC cells drastically repressed tumor growth
in immune-competent mice (Fig. 3d). The disparate effects of
ENTPD2 on in vitro and in vivo cell growth implied that
ENTPD2 might promote tumor growth through shaping the
tumor microenvironment rather than having direct impact on
tumor cell itself. Interestingly, although ENTPD1 and
ENTPD2 share similar functions, demonstrated by ENTPD1- and
ENTPD2-KO tumor models, ENTPD2 had greater effects on
tumor growth, implying that ENTPD2 took the major role in
HCC progression (Supplementary Figs. 6–7). Next, we proceeded
to evaluate the percentages of various immune populations in the
tumors derived from ENTPD2 knockdown and control cells.
Excitingly, we found that knockdown of ENTPD2 in HCC cells
reduced the number of MDSCs in the tumors as represented by
CD11b+Gr+ cell population, but increased the number of CD4+
and CD8+ T-cell populations (Fig. 3e). We further isolated
CD11b+Gr+ cells from the tumors and co-cultured them with
carboxyﬂuorescein succinimidyl ester (CFSE)-labeled CD4+
T cells. The ﬂuorescence intensity of CFSE for each cell would
be halved after cell division. In other words, cell proliferation can
be indicated by halving of the ﬂuorescence intensity of CFSE.
CD11b+Gr+ cells suppressed the proliferation of CD4+ T cells,
indicating that CD11b+Gr+ cells in our tumor models possessed
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Fig. 2 ENTPD2 is a direct transcriptional target of HIF-1α. a Representative IHC staining images of ENTPD2 and two hypoxia markers, CA9 and GLUT1, in
human HCC. Overlapping staining pattern of ENTPD2, CA9, and GLUT1 was observed. b ENTPD2 mRNA expression in MHCC97L-EV, -shHIF-1α, and
shHIF-2α clones. Cells were exposed to 20 and 1% O2 for 24 h and ENTPD2 mRNA expression was quantitated by qRT-PCR. Values were normalized to
20% O2 EV or WT (n= 3). c ENTPD2 mRNA (left) and protein (right) expression in MHCC97L- HIF-1α-WT (parental) and HIF-1α-knockout (HIF-1α−/−)
clones. Cells were exposed to 20 and 1% O2 for 24 h. The mRNA and protein expressions of ENTPD2 were quantitated by qRT-PCR and ﬂow cytometry,
respectively. All values were normalized to 20% O2 WT (n= 3). d Three putative hypoxia-responsive elements (HREs), HIF binding consensus sequence,
5′-A/GCGTG-3′ in the promoter region of ENTPD2 were located by in silico analysis. e ChIP assay was performed in MHCC97L cells exposed to 20 and
1% O2 with IgG, HIF-1α, and HIF-1β antibodies. Fold of enrichment was normalized to the according IgG controls (n= 3). Data are presented as mean± s.d.
(Student’s t-test, ***P< 0.001)
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immunosuppressive activity and are functionally considered
as MDSCs (Fig. 3f). Taken together, these data converged to
support that ENTPD2 promoted HCC tumorigenesis and MDSC
accumulation.
ENTPD2 supports MDSC maintenance through 5′-AMP pro-
duction. To thoroughly investigate how ENTPD2 promoted
MDSC accumulation, we stably overexpressed ENTPD2 using the
CRISPR-dCas9 synergistic activator system (SAM) system
in HCC cells (Supplementary Fig. 8a, b) and collected the
conditioned media to culture the freshly isolated splenic
CD11b+Gr1+ MDSCs from C57BL/6 mice. More CD11b+Gr1+
MDSCs were maintained when cultured in conditioned medium
(CM) collected from ENTPD2-overexpressing HCC cells as
compared with empty vector (EV) control (Fig. 4a). As the
function of ENTPD2 is to dephosphorylate extracellular ATP into
ADP and subsequently into 5′-AMP, we examined the effect of
ENTPD2 on the levels of these extracellular metabolites in
HCC cells. Liquid chromatography-mass spectrometry (LC-MS)
analysis showed that hypoxia increased the rate of extracellular
ATP hydrolysis and the amount of extracellular 5′-AMP in the
CM of both human (MHCC97L) and mouse (Hepa1-6) HCC cell
lines. Meanwhile, those effects were abrogated upon knockdown
and KO of ENTPD2 or inhibition of ENTPD2 by two ENTPD2
inhibitors, ARL67156 and POM-1. These data indicated that
ENTPD2 of cancer cells promoted the conversion of extracellular
ATP to 5′-AMP in the microenvironment (Fig. 4b, c and
Supplementary Fig. 9). To test whether ENTPD2 regulates
MDSCs through 5′-AMP, we cultured CD11b+Gr1+ MDSCs
in the presence of different concentrations of 5′-AMP. Levels of
5′-AMP positively correlated with the amount of CD11b+Gr1+
MDSCs remaining in culture after 4 days (Fig. 4d and Supple-
mentary Fig. 10). It has been reported that MDSCs might
express NT5E, which can further dephosphorylate extracellular
5′-AMP into adenosine that might also promote MDSC accu-
mulation26. However, LC-MS analysis showed that the level of
adenosine in the MDSC culture was undetectable (Supplementary
Fig. 11). We further showed that the presence of competitive
inhibitor of NT5E, APCP, could not abrogate the effect of
5′-AMP on MDSC maintenance (Fig. 4e and Supplementary
Fig. 11). Furthermore, we demonstrated that 5′-AMP could
increase the amount of CD11b+Gr1+ MDSCs induced from bone
marrow progenitors (Fig. 4f). These suggested that 5′-AMP is the
key extracellular metabolite that modulates MDSCs in our
experimental model.
ENTPD2 and 5′-AMP regulate fate of M-MDSC differentia-
tion. CD11b+Gr1+ MDSCs consist of two subsets, CD11b+Ly6C+
M-MDSCs and CD11b+Ly6G+ PMN-MDSCs. During
culture, M-MDSCs tend to differentiate into dendritic cells or
macrophages, whereas PMN-MDSCs fail to differentiate and
undergo apoptosis27, 28. To investigate how 5′-AMP supported
MDSC maintenance, we isolated the two MDSCs subsets from
C57BL/6 mice and examined their individual responses to
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Fig. 3 ENTPD2 promotes tumor growth and MDSC accumulation. a Proliferation rate of MHCC97L-NTC and -shENTPD2 clones in 20 and 1% O2 (n= 3).
BALB/c nude mice were orthotopically implanted with 1 × 106 MHCC97L-NTC, -shENTPD2 clones (n= 5 for each groups). Tumor size was measured with
b caliper and c Xenogen imaging. C57BL/6 mice were orthotopically implanted with 3 × 106 Hepa1-6-EV, -shEntpd2_1, and -shEntpd2_2 clones (n= 5 for
each group). d Tumor size was measured with caliper. e Tumors collected were dissociated. The percentages of CD11b+Gr1+ cells, CD3+CD4+ cells,
and CD3+CD8+ cells in the tumors were determined by ﬂow cytometry (n= 3). f CD11b+Gr1+ cells were isolated from tumor by magnetic cell sorting and
co-cultured with CFSE-labeled splenic CD3+CD4+ cells at different T cell : MDSC ratios. The ﬂuorescence intensity of CFSE for each cell would halve after
cell division. Cell proliferation of T cells was indicated by reduction of CFSE intensity as a result of cell division. The proliferation index of CD3+CD4+ cells
was analyzed by ﬂow cytometry (n= 3). Data are presented as mean± s.d. (Student’s t-test, *P< 0.05, **P< 0.01, ***P< 0.001)
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5′-AMP. 5′-AMP did not affect the survival of PMN-MDSC
and total MDSCs (Fig. 5a and Supplementary Fig. 12). However,
we clearly observed that less M-MDSCs acquired the mature
markers, F4/80 and CD11c, in the presence of 5′-AMP (Fig. 5b, c
and Supplementary Fig. 13a, b). CD11b+Ly6C+F4/80+CD11c+
cells can be identiﬁed as monocyte-derived dendritic cells29. This
suggested that 5′-AMP prevented M-MDSC from maturation.
As APCP could not reverse the phenotype (Fig. 5d), this sug-
gested the effect is mainly associated with 5′-AMP
but not adenosine. To further support this argument, we
compared the effects of 5′-AMP, adenosine, and non-selective
adenosine receptor agonist, 5′-N-ethylcarboxamidoadenosine
(NECA), on M-MDSC maturation. Adenosine had no effect,
whereas NECA only had mild effects (Fig. 5e). Next, to investigate
whether ENTPD2 could regulate the fate of M-MDSC
differentiation in vivo, CFSE-labeled M-MDSCs were sub-
cutaneously co-inoculated with Hepa1-6-EV or shEntpd2
clones into C57BL/6 mice (Fig. 5f). Tumors were dissociated
and the status of CSFE-labeled cells was examined by staining
dendritic cell surface markers followed by ﬂow cytometry
analysis (Fig. 5g). We found that knockdown of ENTPD2 led to
an increase of CFSE-labeled CD11c+ F4/80+ population (Fig. 5g),
suggesting that ENTPD2 prevents M-MDSCs and total MDSCs
from differentiating into dendritic cells. Co-inoculation of
M-MDSCs with ENTPD2 knockdown HCC cells also repressed
tumor growth as compared with control HCC cells (Fig. 5h).
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Consistent results were observed in nude mice (Supplementary
Fig. 13c).
ENTPD2 inhibitor increases efﬁcacy of anti-PD-1/CTLA-4. As
MDSCs could suppress T cells, the presence of MDSCs is often
associated with decrease of T-cell inﬁltration in tumors, thereby
reducing the efﬁciency and efﬁcacy of immunotherapies that
involve the activation of T cells. CTLA-4 (cytotoxic T
lymphocyte-associated protein 4) and PD-1 (programmed cell
death receptor 1) are the most hotly pursued and widely studied
immune checkpoint receptors for immunotherapies in cancers30.
CTLA-4 and PD-1 are inhibitory receptors of T cells30. CTLA-4
prevents activation of T cells by competing with CD28 (stimu-
latory T-cell receptor) for their ligands CD80 and CD8630. PD-1,
upon stimulation by its ligands PD-L1 and PD-L2, which are
often expressed in cancer cells, inhibits kinases involved in T-cell
activation30. Anti-CTLA-4 antibody (Ipilimumab) and anti-PD-1
antibody (Nivolumab) were ﬁrst approved by Food and Drug
Administration for the treatment of melanoma and have
remarkable long-term survival beneﬁts in cancer patients,
whereas their efﬁciency and efﬁcacy in HCC patients are still
unknown30. We hypothesize that blockade of ENTPD2 in cancer
cells would impair MDSC maintenance and enhance T-cell
penetrance in the tumors, thereby improving the effectiveness of
immune checkpoint therapies in cancer treatment. Single treat-
ment of ENTPD2 inhibitors, ARL67156 and POM-1, markedly
reduced growth of Hepa1-6-derived HCC in C57BL/6 syngeneic
model (Fig. 6a). Notably, POM-1 has a slightly greater inhibitory
effect on HCC as compared with ARL67156. POM-1 can inhibit
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both ENTPD1 and ENTPD2. To address whether the tumor
inhibitory effects of POM-1 are mediated through ENTPD2, we
inoculated Entpd1 KO HCC cells into C57BL/6 mice. We found
that POM-1 could still signiﬁcantly repress HCC growth in the
tumors without Entpd1, suggesting that POM-1 inhibited HCC
growth through Entpd2 in Hepa1-6 (Supplementary Fig. 14). As
combined treatments of anti-CTLA-4 and anti-PD-1 antibodies
have been demonstrated to be more effective in activating T cells
within the tumors than single antibody treatment in mouse
melanoma model31, as proof-of-concept we examined the effect
of combined immune checkpoint inhibitors (anti-CTLA-4 and
anti-PD-1) with POM-1. Combination of POM-1 and the two
immune checkpoint inhibitors (Com) achieved the highest tumor
suppressive responses (Fig. 6b). Tumor-associated MDSCs were
signiﬁcantly reduced by either POM-1 or immune checkpoint
inhibitors treatment (Fig. 6c). Collecting the tumors at a longer
time point, we found that the incidence of regression was
signiﬁcantly elevated by single treatments and, to even a greater
extent, by combined treatment (Fig. 6d). Furthermore, combi-
nation of POM-1 and immune checkpoint inhibitors signiﬁcantly
increased inﬁltration of lymphocytes (white arrows) and reduced
tumor cells (black arrows) (Fig. 6d). To study the effects of
immune checkpoint inhibitors for an extended period of time, we
employed a chemically induced mouse HCC models with nitro-
sodiethylamine (DEN) and carbon tetrachloride (CCl4). In this
model, we further demonstrated combined treatment could
maximize the survival of the HCC-bearing mice (Fig. 6e). Taken
together, our study suggests inhibition of ENTPD2 as a promising
strategy to increase the efﬁcacy of PD-1/CTLA-4 immune
checkpoint inhibitor in cancer treatment.
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twice weekly (n= 5 for each group). Data are presented as mean± s.d. (Student’s t-test, *P< 0.05, **P< 0.01, ***P< 0.001)
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Discussion
The microenvironment of tumor is composed of various types of
immune cells such as T cells, dendritic cells, and NK cells, which
function to kill cancer cells. However, these immune cells are
often exhausted or repressed by populations of immune
suppressive cells such as Tregs and MDSCs leading to escape of
immune surveillance of tumors. MDSCs are abundantly found in
HCC1, 2. In general, there are at least two possible strategies to
eradicate tumor-inﬁltrating MDSCs—preventing MDSC recruit-
ment and promoting MDSC maturation32. Using HCC as a
model, we previously demonstrated hypoxia as a central driver for
MDSC accumulation in tumors and showed that hypoxic cancer
cells secreted CCL26 to attract MDSCs33. Blockade of CCL26
cognate receptor, CX3CR1, by neutralizing antibody prevented
MDSC inﬁltration and perturbed tumor growth. In this current
study, we further revealed that hypoxia prevented MDSC
maturation upon their arrival at tumor sites. We demonstrated
that hypoxia induced ENTPD2 in cancer cells to generate a
5′-AMP-rich microenvironment to keep MDSC undifferentiated
(Fig. 7).
Extracellular 5′-AMP is known to be catabolized into adeno-
sine by ectoenzyme NT5E (CD73), which is widely expressed in
endothelial cells, epithelial cells, several immune cells (mainly
Treg cells and MDSCs), as well as tumor cells. Adenosine has an
extensive impact on both lymphoid and myeloid lineages. For
lymphocytes, adenosine was shown to decrease granule
exocytosis-induced cytotoxicity and cytokine production of CD8+
effector T cells and to shift the polarization of CD4+ helper cells
towards Tregs instead of Th1 cells34–36. For myeloid cells,
adenosine was demonstrated to promote and maintain alternative
macrophage activation via A2B adenosine receptor so that
M2 macrophages exhibit more potent immunosuppressive
activity37–39. Notably, adenosine was also demonstrated to induce
the expansion of PMN-MDSCs from bone-marrow myeloid
progenitors and facilitate their ability to suppress T-cell
proliferation with no observable effects on M-MDSCs26.
Although adenosine and NT5E were extensively investigated in
myeloid cells, the effects of 5′-AMP are largely unknown.
Intriguingly, our data showed that ENTPD2 but not NT5E was
signiﬁcantly upregulated in HCC, further highlighting the
importance of ENTPD2 and 5′-AMP in microenvironment
formation and cancer development. More excitingly, we provided
evidence showing that hypoxia induces ENTPD2 through
HIF-1α. Mechanistically, we unambiguously showed that 5′-AMP
prevented M-MDSCs from differentiating into dendritic cells
in vitro and in vivo. In concordance with our clinical observation
of ENTPD2 overexpression, we further showed that NT5E inhi-
bitor could not prevent the 5′-AMP-induced MDSC main-
tenance, suggesting that ENTPD2 but not NT5E is critical for
MDSC maintenance in the context of cancer.
MDSCs, especially M-MDSCs, can differentiate into either
immune suppressive M2 macrophages or non-immune suppres-
sive dendritic cells and M1 macrophages in tumors in the
presence of speciﬁc cytokines. Stimulating the differentiation of
MDSC into non-immune suppressive cells is an attractive anti-
cancer strategy32. All-trans retinoic acid (ATRA), a metabolite of
vitamin A, is a well-studied promoter of myeloid cell differ-
entiation. ATRA can stimulate MDSCs into mature myeloid
cells40 and also decrease their immunosuppressive activities via
ERK1/2 kinase pathway;41 however, ATRA simultaneously
induces the expansion of Treg cells42, another important immune
suppressive population, precluding ATRA from being a suitable
anti-cancer drug. Accumulative studies converged to show that
hypoxia is a key factor, which determines the fate of tumor-
inﬁltrating myeloid cell. A recent study showed that hypoxia
increased sialic acid transport to cell membranes of MDSCs,
promoting sialyation-mediated CD45 dimerization and therefore
its activation. This led to downregulation of STAT3 activity,
which consequently promoted the differentiation of M-MDSCs
into tumor-associated macrophages (TAMs) or M2 macro-
phages43. Apart from being able to differentiate into TAMs as
shown by others, our study has unambiguously indicated that
hypoxia-induced ENTPD2 upregulation and subsequent 5′-AMP
enrichment prevented the differentiation of M-MDSCs into
HRE ENTPD2
HIF-1α
HIF-1βA/GCGTG
ATP ADP AMP
ENTPD2
Hypoxic HCC cells
Monocytic
MDSCs
Monocyte-derived
dendritic cells
DifferentiationExtracellular 5′-AMP
Hypoxia
Fig. 7 Schematic representation of hypoxia-induced MDSC accumulation. Hypoxia stabilizes HIF-1α in cancer cells. HIF-1α binds to the HRE in the promoter
of ENTPD2 to initiate transcription in cancer cells. ENTPD2 facilitates the dephosphorylation of extracellular ATP into 5′-AMP. Increase in extracellular
5′-AMP prevents M-MDSCs from maturation at tumor sites, thereby promoting tumor-mediated immune escape. Inhibition of ENTPD2 reduces the
number of tumor-inﬁltrating MDSCs and increase the efﬁcacy of PD-1/CTLA-4 immune checkpoint inhibitors
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00530-7 ARTICLE
NATURE COMMUNICATIONS |8:  517 |DOI: 10.1038/s41467-017-00530-7 |www.nature.com/naturecommunications 9
non-immune suppressive CD11c+ dendritic cells in vivo. Both
M-MDSCs and TAMs are immunosuppressive and pro-angio-
genic, but M-MDSCs are maintained via 5′-AMP, whereas TAMs
are maintained via adenosine37–39. The effects of 5′-AMP on
alternative macrophage activation still remains to be addressed.
Notably, our current study highlighted the mechanism by which
hypoxia/HIF-1 in cancer cells signals MDSC. HIF-1 in MDSCs
could regulate their intrinsic functions. HIF-1 itself or through
its transcriptional target, microRNA-210, enhanced MDSC
suppressive abilities by promoting their own arginase and nitric
oxide production44. Our studies together with others have
unraveled the multiple functions of hypoxia/HIF on MDSC in
cancers and provided evidence that hypoxia is a critical
modulator of the tumor stroma.
Recent clinical success of the anti-PD-1 and anti-CTLA-4
immune checkpoint inhibitors has offered an optimistic future for
cancer patients. Considerable research effort is now underway to
improve the efﬁcacy of immunotherapies. As immune checkpoint
inhibitors harness T cells to eradicate cancer cells, the presence of
tumor-inﬁltrating T cells would theoretically improve the efﬁcacy
of immunotherapies. A multitude of studies suggested that
patients with immunological (or T-cell-inﬁltrated) tumors
respond better to immune checkpoint inhibition as compared
with patients with non-immunological (or non-T-cell-inﬁltrated)
tumors45. An important pathological study indicated that MDSCs
or their derivative TAMs geographically localized in between
the margin of CD8+ effector T cells and cancer cells, dampening
T-cell inﬁltration46. Recent studies indicated that melanoma
patients with lower number of M-MDSCs prior treatment
responded better to Ipilimumab47, 48. These clinical evidences
strongly suggested that MDSCs act as a barricade to protect
tumors from immunosurveillance. Eradicating MDSCs should
enhance the efﬁcacy of cancer immunotherapy. One pioneer
study demonstrated that blocking CXCR2 disrupted PMN-MDSC
trafﬁcking to tumor sites and sensitized the tumors to anti-PD-1
treatment in mice;7 however, this approach speciﬁcally targeted
PMN-MDSCs but not M-MDSCs and TAMs. Worth mentioning,
M-MDSCs are capable to differentiate into PMN-MDSCs in
tumor-bearing mice49. Therefore, targeting M-MDSCs should
be a more preferable therapeutic strategy. Our study identiﬁed
ENTPD2 as a critical factor in M-MDSC maintenance and
we showed that ENTPD2 inhibitor POM-1 suppressed both
M-MDSCs and PMN-MDSCs, and sensitized the tumors to anti-
PD-1/anti-CTLA-4 immune checkpoint inhibitors.
In summary, our study discloses that hypoxia/HIF-1α induces
ENTPD2 in cancer cells to increase the extracellular level of
5′-AMP, which prevents M-MDSCs from maturation, therefore
maintaining MDSC undifferentiated in the tumor stroma.
Inhibition of ENTPD2 by speciﬁc inhibitors can stimulate
M-MDSC differentiation into dendritic cell, shifting the stromal
cell components from immune suppressive into non-immune
suppressive. Our results provide a rationale to devise strategy
against MDSCs and increase the efﬁcacy of PD-1/CTLA-4
checkpoint inhibition immunotherapy.
Methods
Patient samples and cell lines. Human HCC and their paired NT liver samples
were collected during surgical resection at Queen Mary Hospital. The use of human
samples was approved by the Institutional Review Board of the University of Hong
Kong/ Hospital Authority Hong Kong West Cluster. The patients were explained
and they signed consent forms to acknowledge the use of their resected tissues for
research purposes. Human HCC cell line MHCC97L was a gift from Fudan
University (Dr Z.Y. Tang) of Shanghai. Human HCC cell lines PLC/PRF/5 and
Hep3B and murine HCC cell line Hepa1-6 were purchased from American Type
Culture Collection. All cell lines were cultured in Dulbecco’s modiﬁed Eagle
medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cell cultures
were routinely tested for mycoplasma infection.
Establishment of knockdown, KO and overexpression HCC cells. Mouse
Entpd2, ENTPD2, and HIFs knockdown HCC cells were generated by lentiviral-
mediated shRNA approach. Oligonucleotides encoding shRNAs targeting
ENTPD2, mouse Entpd2, HIF-1α, HIF-2α, non-target control (NTC) were inserted
into pLKO.1-puro vector50. pLKO plasmids were transfected into HCC cells and
selected with puromycin for 7–14 days. HIF-1α-stable KO HCC cell lines were
established by TALEN approach. HIF-1α-speciﬁc TALE domains were designed by
E-TALEN software51, assembled and cloned into pTALEN v2 vector by “TALE
Toolbox”52. HIF-1α KO construct was transfected into MHCC97L HCC cells,
respectively. Stable cells were clonally expanded. Frame-shift mutations in the
stable KO cells were conﬁrmed by SURVEYOR mutation detection kit (Transge-
nomic, Inc.) and DNA sequencing. Human ENTPD1/2 and mouse Entpd1/2 stable
KO HCC cell lines were established by lentiviral-based CRISPR gene-editing
system (lentiCRISPR v2) obtained as a gift from Zhang and colleagues53. We
sequentially and stably transfected Cas9 and single-guide RNAs (sgRNAs) targeting
the ﬁrst exon of ENTPD1/2 or Entpd1/2 into MHCC97L or Hepa1-6 cells. The KO
efﬁciency was conﬁrmed by ﬂow cytometry. For ENTPD2 overexpressing system,
we employ the CRISPR-dCas9 SAM54. We sequentially and stably transfected
dCas9-VP64, MS2-p65-HSF1, and sgRNAs targeting the promoter of ENTPD2
into MHCC97L cells, as described54. shRNA and sgRNA sequences are provided in
Supplementary Table 1.
Antibodies and recombinant proteins. Sources of the antibodies for ﬂow
cytometry analysis are listed as follow: mouse Fc Block (1:100; 553142; BD
Biosciences), mouse CD45 (1:100; clone 30-F11; Biolegend), mouse Gr1 (1:100;
clone RB6-8C5; Biolegend), mouse CD11b (1:100; clone M1/70; eBiosciences),
mouse CD11c (1:100; clone N418; Biolegend), mouse F4/80 (1:100; clone MB8;
Biolegend), mouse Ly6G (1:100; clone 1A8; Biolegend), mouse Ly6C (1:100; clone
HK1.4; Biolegend), human ENTPD2 (1:25; PA5-26333; Sigma-Aldrich), mouse
Entpd2 (1:25; ab150503; Abcam), human ENTPD1 (1:100; clone A1; Biolegend),
and mouse Entpd1 (1:100; clone Duha59; Biolegend). Sources of the antibodies for
immunohistochemistry are listed as follow: human ENTPD2 (1:200; ab150503;
Abcam), human GLUT1 (1:1000; ab15309Abcam), and human CA9 (1:500;
ab1508L; Abcam).
Animal studies. For orthotopic implantation, 1 × 106 luciferase-labelled
MHCC97L cells were injected into the left lobes of the livers of 5–7-week-old male
BALB/c nude mice, whereas 3 × 106 Hepa1-6 cells of C57BL/6 mice. Mice were
administered with 100 mg kg−1 D-luciferin (Caliper) via intraperitoneal (i.p.)
injection before bioluminescent imaging using Xenogen IVIS 100 Imaging System.
Tumors were collected for ﬂow cytometry analysis. For drug treatment in
orthotopic implantation tumor model, C57BL/6 mice were orthotopically
implanted with Hepa1-6 cells and 3 days after the operation were administered
with (1) vehicle, 3 mg kg−1 ARL67156 (Tocris Bioscience) or 10 mg kg−1 POM-1
(Tocris Bioscience) through i.p. injection for 8 consecutive days, and (2) 4 mg kg−1
control IgG antibody or 2 mg kg−1 PD-1 (clone RMP1-14; BioXCell, West
Lebanon, NH) and CTLA-4 (clone 9D9; BioXCell) monoclonal antibodies through
i.p. injection on day 5 and day 9. For drug treatment in chemically induced tumor
model, 2-week-old C57BL/6 mice were administered with single dose of 1 mg/kg
DEN through i.p. injection (Sigma-Aldrich) and after 8 weeks, with 1.25 ml kg−1
30% CCl4 (Sigma-Aldrich) through i.p. injection twice weekly for 8 weeks. CCl4
(100%) were diluted in olive oil. Twenty-six-week-old mice were with administered
10 mg kg−1 POM-1 through i.p. injection thrice weekly or 2 mg kg−1 PD-1and
CTLA-4 monoclonal antibodies through i.p. injection twice weekly. For in vivo
tracing the fate of MDSCs, freshly isolated M-MDSCs or total MDSCs were labelled
with 5 µM CFSE dye (Thermo Fisher Scientiﬁc). Labeled 5 × 105 M-MDSCs or
1 × 106 total MDSCs were co-injected with 2 × 106 Hepa1-6 cells into the ﬂanks of
C57BL/6 mice. Tumors sizes were measured with caliper and calculated with
formula: length × width × depth × 0.52 (mm3). All animal studies were approved
by the Committee on the Use of Live Animals in Teaching and Research, the
University of Hong Kong, and performed under the Animals (Control of
Experiments) Ordinance of Hong Kong.
Hypoxia and generation of CM medium. Hypoxic environment was created by
culturing cells in 1% O2/ 5% CO2 in a modulator incubator chamber at 37 oC. To
generate CM for MDSC culture, MHCC97L cells were cultured in serum-free
DMEM medium and exposed to 20% O2 or 1% O2 for 24–48 h. Supernatants were
collected and puriﬁed by 0.20 µm ﬁlter. To generate CM for LC-MS, MHCC97L or
Hepa1-6 cells were cultured in full medium and exposed to 20% O2 or 1% O2 for
48 h. Cells were trypsinized and washed with phosphate-buffered saline (PBS).
Cells (2 × 106) were re-suspended in serum-free DMEM medium supplemented
with 100 µM ATP and incubated at 37 °C for 1 h. Media were collected and puriﬁed
by 0.20-µm ﬁlter.
Preparation of single cell suspensions. Before magnetic bead cell sorting and
ﬂow cytometry analysis, single cell suspensions were prepared. Brieﬂy, spleens and
tumors collected from Hepa1-6-bearing C57BL/6 mice were dissociated with
gentleMACS dissociator (Miltenyi Biotech) according to the manufacturer’s
instruction. Total bone marrow cells were freshly isolated from femurs and tibias
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of C57BL/6 mice by ﬂushing with PBS. The resulting cell suspensions were
ﬁltered through 70 µm cell strainers and treated with ACK lysing buffer (Life
Technologies) to remove red blood cells according to the manufacturer’s
instruction.
MDSC isolation by magnetic bead cell sorting. Isolation of CD11b+Gr1+ total
MDSCs, CD11b+Ly6C+ M-MDSCs, and CD11b+Ly6G+ PMN-MDSCs were carried
out with mouse MDSC isolation kit (Miltenyi Biotech) according to the
manufacturer’s instruction. In brief, after treatment with FcR Blocking Reagent,
cells were stained with biotin-conjugated Gr1 or Ly6G antibody and further labeled
with anti-biotin microbeads. The labeled cells were passed through the MS
separation column (Miltenyi Biotech) for magnetic cell separation. The retained
cells were analyzed for CD11b+Gr+/CD11b+Ly6C+/CD11b+Ly6G+ population to
evaluate for MDSC purity (>90%) by ﬂow cytometry.
MDSC culture and maintenance. Freshly isolated splenic MDSCs or bone
marrow progenitors were cultured in RPMI-1640 medium supplemented with
10% FBS, 10 ng ml−1 granulocyte–macrophage colony-stimulating factor (R&D
Systems), 10 ng ml−1 interleukin-4 (R&D Systems), and 50 µM 2-mercaptoethanol
(Sigma-Aldrich), alone or in the presence of 100 µM 5′-AMP (Sigma-Aldrich),
100 µM APCP (Tocris Bioscience), 100 µM adenosine (Sigma-Aldrich), 100 µM
NECA (Tocris Bioscience), or HCC cell CM.
Immunohistochemistry. Before parafﬁn embedding, human/mouse livers were
ﬁxed with 10% formalin and washed with 75% ethanol. Parafﬁn sections were
dewaxed with xylene and rinsed with ethanol. Antigens were retrieved in EDTA
buffer by boiling. Sections were stained with primary antibodies overnight at 4 oC
and horseradish peroxidase-conjugated secondary antibodies (Dako) for 30 min
at room temperature. Sections were developed with 3, 3′-diaminobenzidine
(Sigma-Aldrich) and counterstained with hematoxylin. For histological analysis,
dewaxed sections were counterstained with hematoxylin and eosin.
Quantitative real-time PCR. Total RNA was extracted by TRIzol and
complementary DNA was prepared using GeneAmp Gold RNA PCR Core Kit
(Applied Biosystems). Quantitative real-time PCR ampliﬁcation of ENTPD2 and
the internal control HPRT were performed using the Taqman Gene Expression
Assay for clinical specimens and using SYBR Green qPCR Master Mix (Applied
Biosystems) with speciﬁc primers provided in Supplementary Table 2 for other
expression studies.
Clinicopathological correlation. The mRNA level of ENTPD2 in HCC patients
was correlated with different clinicopathological parameters in HCC patients by
SPSS20.0 software (SPSS, Inc.)56. Brieﬂy, the parameters were analyzed by
pathologist upon surgical resection. The clinicopathological parameters included
venous invasion, direct liver invasion, tumor size, absence of tumor encapsulation,
presence of tumor microsatellite formation, cellular differentiation by Edmondson
grading, and association with hepatitis B infection. Clinicopathological correlations
of ENTPD2 expression were performed with Student’s t-test. Survival test was done
by Kaplan–Meier curve and log-rank test. P< 0.05 was considered statistically
signiﬁcant.
Flow cytometry analysis. Cells were incubated with anti-mouse Fc Block for
10 min at room temperature and stained with ﬂuorophore-conjugated antibodies
for 45 min at 4 oC in staining buffer (PBS with 0.5% bovine serum albumin, and
2 mM EDTA). Labeled cells were washed with staining buffer twice and analyzed
by BD FACSCantoII Analyzer (BD Biosciences) and FlowJo software (FlowJo).
Staining condition of other dyes for functional assays were described individually.
HCC cell proliferation assay. The proliferation rate of HCC cell line was
measured by cell counting. For both MHCC97L and Hepa1-6 subclones,
2 × 104 cells were seeded on 12-well culture plates and cultured in 20 and 1% O2 for
4 days. Cells were trypsinized and counted with Z1 coulter particle counter
(Beckman Coulter) daily.
T-cell proliferation assay. Isolation of CD4+CD3+ T cells was carried out with
mouse T-cell isolation kit (R&D Systems) according to the manufacturer’s
instruction. Isolated T cells were stained with 2 µM CSFE for 10 min and
subsequently co-cultured with freshly isolated CD11b+Gr1+ MDSCs in different
ratios (1:1; 2:1; 4:1, and 1:0) for 3 days. The ﬂuorescence intensity of CFSE for each
cell would halve after cell division. Number of cell division of each cell was
analyzed by ﬂow cytometry.
ChIP assay. MHCC-97L cells were crosslinked with formaldehyde, lysed with
SDS buffer and sonicated. Sheared DNA was precleared with salmon sperm
DNA/protein A agarose slurry (Merck Millipore) and immunoprecipitated
with HIF-1α, HIF-1β, and IgG (Santa Cruz). Agarose beads were incubated with
antibody/protein/DNA complex and washed with low-salt buffer, high-salt buffer,
and LiCl wash buffer according to the manufacturer’s protocol (Millipore). DNA
was eluted in 1% SDS/0.1 M NaHCO3 and de-crosslinked with 0.2 M NaCl.
ATP and 5′-AMP measurements. The amounts of ATP, 5′-AMP and adenosine
in CM were quantiﬁed by liquid chromatography–tandem mass spectrometry
(LC-MS). CM from cells were collected and mixed with methanol. For LC-MS
analysis, the metabolites were reconstituted in 50% methanol (v/v). The chroma-
tographic separation was performed in a hypercarbon analytical column at a ﬂow
rate of 200 µl min−1. The samples were separated using a mobile phase consisting of
10 mM ammonium acetate in water (solvent A) and in acetonitrile (solvent B) that
were adjusted with ammonia to pH 10.0. The gradient elution was performed in
98% solvent A decreased to 50% solvent A in 10 min and then back to 98% solvent
A in 10 min. Eluted metabolites were analyzed in the multiple reaction monitoring
(MRM) mode using 3200 QTRAP System (Applied Biosystems Sciex). Standard
of 5′-AMP and ATP (Sigma) was used for optimization. The MRM transition of
5′-AMP was set m/z 345.95/134.10 and ATP was set m/z 506.00/159.00. The
amount of 5′-AMP was represented by the area of analyst peak.
Statistical analysis. Data are expressed as mean ± SD and analyzed by Student’s
t-test. P-values <0.05 were considered signiﬁcant.
Data availability. The TCGA data reference ion this study are available in the
cBioPortal for Cancer Genomics website http://www.cbioportal.org/. The authors
declare that all the other data supporting the ﬁndings of this study are available
within the article and its Supplementary Information ﬁles and from the
corresponding author upon reasonable request.
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